EGFR and cancer: When cetuximab (an EGFR target inhibitor) was combined with avelumab (a PD-L1 target inhibitor) to treat NSCLC, the anti-cancer mechanism of these two antibodies partially depended on the activation of the ADCC and cGAS-STING pathways driven by NK cells (134).